An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus
Public ClinicalTrials.gov record NCT00135330. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Evaluation of the Metabolic Effects of Exenatide, Rosiglitazone, and Exenatide Plus Rosiglitazone in Subjects With Type 2 Diabetes Mellitus Treated With Metformin
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This protocol is designed to evaluate the metabolic effects of adding exenatide, rosiglitazone, or both to an existing regimen of metformin in subjects with inadequate glycemic control.
Study identification
- NCT ID
- NCT00135330
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 137 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2005
- Primary completion
- Jun 30, 2008
- Completion
- Jun 30, 2008
- Last update posted
- Apr 6, 2015
2005 – 2008
United States locations
- U.S. sites
- 19
- U.S. states
- 12
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Phoenix | Arizona | — | — |
| Research Site | San Francisco | California | — | — |
| Research Site | Jacksonville | Florida | — | — |
| Research Site | Orlando | Florida | — | — |
| Research Site | Atlanta | Georgia | — | — |
| Research Site | Honolulu | Hawaii | — | — |
| Research Site | Indianapolis | Indiana | — | — |
| Research Site | Boston | Massachusetts | — | — |
| Research Site | Pittsfield | Massachusetts | — | — |
| Research Site | Minneapolis | Minnesota | — | — |
| Research Site | Rochester | Minnesota | — | — |
| Research Site | Syracuse | New York | — | — |
| Research Site | The Bronx | New York | — | — |
| Research Site | Cincinnati | Ohio | — | — |
| Research Site | League City | Texas | — | — |
| Research Site | New Braunfels | Texas | — | — |
| Research Site | San Antonio | Texas | — | — |
| Research Site | Renton | Washington | — | — |
| Research Site | Spokane | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00135330, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 6, 2015 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00135330 live on ClinicalTrials.gov.